Disney Plans to Cut 1,000 Jobs Amid Ongoing Restructuring Efforts 
Chinese Brands Are Taking Over Brazil — And It's Just Getting Started 
SanDisk Joins Nasdaq-100, Replacing Atlassian on April 20 
San Francisco Suspect Arrested After Molotov Cocktail Attack on OpenAI CEO Sam Altman's Home 
Pilots Fear Retaliation for Refusing Middle East Flights Amid Ongoing Conflict 
Meta Is Building an AI Version of Mark Zuckerberg to Interact With Employees 
Rio Tinto's California Boron Assets Attract Over a Dozen Bidders, Valued at Up to $2 Billion 
Chalco Stock Surges as Q1 2025 Profit Forecast Jumps Up to 58% 
TSMC Posts Record Q1 2026 Profits Driven by Surging AI Chip Demand 
Anthropic's Mythos AI Model Sparks Emergency Cybersecurity Meeting With Top U.S. Bank CEOs 
China's AI Stocks Surge as Zhipu and MiniMax Hit Record Highs 
MATCH Act: How New U.S. Chip Legislation Could Freeze China's Semiconductor Ambitions 
Kia Cuts EV Sales Target for 2030 Amid Slowing Demand and U.S. Policy Shifts 
Chinese Cars in Europe: Consumer Trust Is Shifting Fast 
Jefferies Upgrades Starbucks to Hold as China JV Deal Closes and U.S. Business Shows Signs of Recovery 
Volkswagen Q1 2026 Sales Decline Amid China and U.S. Market Pressures 
WASHINGTON, April 11, 2016 -- Tomorrow, the Regenerative Medicine Foundation (RMF) will co-host an event with the Bipartisan Policy Center (BPC) on advancing the availability and use of safe and effective regenerative cell therapies in the United States. The April 12th event, Advancing a New Policy Framework for Regenerative Cell Therapy—which begins at 9:30am EST and will be webcast live—will bring together scientific and academic experts, patients, practitioners, and industry to discuss the science behind cell therapy and new policies needed to modernize the current U.S. regulatory approach.
In addition to co-hosting the event, the Regenerative Medicine Foundation is collaborating with BPC to convene and engage a broad societal-based alliance of non-profit patient groups, medical philanthropies, academic centers, industry organizations, and other advocates to support a new regulatory pathway for safe and effective cell therapies in the U.S.
"With the recent introduction of the bipartisan, bicameral REGROW Act, the time has arrived for us to move from laboratories into the clinic," said Bernie Siegel, executive director of the Regenerative Medicine Foundation and founder and chair of the annual World Stem Cell Summit & RegMed Capital Conference. "Cell therapies are different from drugs, and they have the vast potential to alleviate human suffering. We need to support the FDA in accelerating safe and effective cell therapy treatments, and the Regenerative Medicine Foundation is committed to this humanitarian cause."
"We are delighted to be working with the Regenerative Medicine Foundation to advance regenerative cell therapy—which represents one of the most promising areas for the next generation of groundbreaking treatments," said Janet Marchibroda, director of BPC's health innovation initiative. "Through our work together, we are advancing public policy that will accelerate the availability of safe and effective treatments for Americans and improve U.S. competitiveness in the global marketplace."
About the Regenerative Medicine Foundation
The nonprofit Regenerative Medicine Foundation, formerly known as the Genetics Policy Institute, is an influential global network of stakeholders from patient-advocacy, science, and industry that serves as a catalyst and provides leadership to the pro-cures movement. Through RMF's action network, reports, newsletters, the flagship World Stem Cell Summit and RegMed Capital Conference, special projects, speaking engagements, world-renowned advisory boards, educational resources, teaching initiatives, and strategic relationships, RMF serves as the foremost channel of knowledge between leading regenerative medicine experts, patient advocates, and those who make policy for the general public.
CONTACT: Alan Fernandez
650-759-8300
[email protected]
